A Two Part Study to Investigate the Safety and Immunogenicity of the VAX125 Influenza Vaccine in Healthy Adults Age 18-49 Years Part I: Phase I, Open-Label, Escalating Dose-Ranging Study Part II: Phase II, Double-Blind Placebo-Controlled Study
Phase of Trial: Phase I/II
Latest Information Update: 11 Nov 2014
At a glance
- Drugs VAX 125 (Primary)
- Indications Influenza A virus infections
- Focus Adverse reactions
- Sponsors VaxInnate
- 17 Jun 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 28 Apr 2009 Results reported in a VaxInnate media release. Phase I results will also be presented at the National Foundation for Infectious Diseases' Twelfth Annual Conference on Vaccine Research.
- 04 Sep 2008 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History